Silence Therapeutics plc (SLN) Tops Q1 EPS by 3c

Silence Therapeutics plc (NASDAQ: SLN) reported Q1 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $1.32 million.

For earnings history and earnings-related data on Silence Therapeutics plc (SLN) click here.

You May Also Be Interested In

• B.Riley Upgrades Compass Diversified (CODI) to Buy, 'More Constructive Outlook Set Up 2027'
• Cardinal Infrastructure Group Inc. (CDNL) Misses Q2 EPS by 2c ; Offers Guidance
• Axsome Therapeutics (AXSM) PT Raised to $275 at Guggenheim